Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 in Moderate to Severe Plaque Psoriasis
NCT06061471Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gumokimab in plaque psoriasis, sponsored by Akeso, Inc.. Started Sep 2023; status: completed.
02
Drugs
gumokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06061471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061471.